
Opinion|Videos|March 20, 2025
EGFR mNSCLC: Future Directions
Panelists discuss how despite significant advances in EGFR-targeted therapy, critical unmet needs persist in EGFR-positive non–small cell lung cancer (NSCLC), including the need for better strategies to combat resistance mechanisms, more effective treatments for brain metastases, improved options for uncommon EGFR mutations, and the development of biomarker-driven approaches to optimize sequencing of available therapies.
Advertisement
Video content above is prompted by the following:
- What is your perspective on the unmet needs in EGFR-positive NSCLC, and how could future trials address these
Advertisement
Related to this article

Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.

Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.

Long-term data show that plixorafenib yielded durable responses and no cumulative adverse effects in BRAF-altered primary central nervous system tumors.

The FDA approved durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer.

The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.

A European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
2
Cardiovascular and Bleeding Risk With BTK Inhibitors in CLL
3
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
4
Dr Calais on Individualizing PSMA-Targeted Therapy Sequencing in Prostate Cancer
5


